RBM20 variants disrupt Ca2+ handling and metabolism in dilated and non-compaction cardiomyopathy stem cell models
Year: 2026
Type: article
Abstract: Mutations in the splice-regulator RBM20 cause heart failure with reduced ejection fraction (HFrEF), typically manifesting as dilated cardiomyopathy (DCM). Mutations at position 634 in the RS-domain cause DCM with (R634L) or without (R634W) left ventricular non-compaction (LVNC). However, the mechanisms underlying phenotype variability and personalized therapy beyond HFrEF remain unclear. We generated induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM), 3D-cardiospheres and engineered myocardial tissues from patients with RBM20 mutations R634L (LVNC) or R634W (DCM). Using CRISPR/Cas9, we created isogenic rescue and mutation-insertion lines, identifying RBM20 mis-localization, splicing errors in TTN and RYR2 , and sarcomere irregularities in both. DCM-CM showed increased resting Ca 2+ leak and reduced Ca 2+ transient amplitude, typical of HFrEF, and spatial disorganization of sarcoplasmic reticulum and mitochondria. In contrast, LVNC-CM exhibited elevated Ca 2+ transient amplitude with faster kinetics, driven by elevated cAMP and mis-spliced, hyperactive CAMK2D, leading to PLN-hyperphosphorylation and increased metabolic respiration. Further, LVNC showed desmosomal derangement potentially from mis-splicing of Junction plakoglobin and reduced 3D cardiosphere compaction. Despite distinct mechanisms, contractile force was reduced in both. Isogenic controls confirm mutation causality. Drug intervention with verapamil partially improved selected abnormal Ca 2+ handling and contractile phenotypes in LVNC- and DCM-CM, whereas the CAMK2D inhibitor AIP improved systolic Ca 2+ handling predominantly in LVNC-CM. In conclusion, different amino acid substitutions at the same RBM20-residue induce opposing Ca 2+ -handling and structural phenotypes. While DCM features impaired Ca 2+ handling, LVNC shows defective cell-cell coupling and activated Ca 2+ handling and metabolism, yet insufficient to compensate for organ-level dysfunction. This supports personalized pharmacological therapies in early HF, and potential CRISPR/Cas9 repair for RBM20 cardiomyopathy.
Authors: Sabine Rebs, Farbod Sedaghat-Hamedani, Elham Kayvanpour, Hanna Eberl, Branimir Berečić, Jan Dudek, Nicole Wagensohner, Aylin Seedorf, Julia K. Unsöld, Daniela Hübscher, Christoph Reich, Teresa Klein, Sören Doose, Viacheslav O. Nikolaev, Tjark Buchwald, Ahmed Wagdi, Michael Kohlhaas, Nataliya Dybkova, Patricia Morais Costa, Kaomei Guan, Gerd Hasenfuss, Eva A. Rog-Zielinska, Samuel Sossalla, Markus Sauer, Christoph Maack, Malte Tiburcy, Benjamin Meder, Katrin Streckfuss-Bömeke
Institutions: University of Würzburg, Universitätsmedizin Göttingen, German Centre for Cardiovascular Research, Heidelberg University, University Hospital Heidelberg, Universitätsklinikum Würzburg, Multiscale Bioimaging, University of Göttingen, University Medical Center Hamburg-Eppendorf, University of Freiburg, University Medical Center Freiburg, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Technische Universität Dresden, Justus-Liebig-Universität Gießen, Kerckhoff Klinik, Cardio-Pulmonary Institute, Stanford University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: RBM20, dilated cardiomyopathy, left ventricular noncompaction, heart failure with reduced ejection fraction, calcium handling, calcium transients, calcium leak, splicing errors, titin, RyR2, CAMK2D, cAMP signaling, desmosomes, plakoglobin, sarcomere, cardiomyocyte contractility, verapamil, AIP, iPSC-derived cardiomyocytes
Open Access status: gold
Estimated APC paid: $3,790
Funders: Deutsches Zentrum für Herz-Kreislaufforschung, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Else Kröner-Fresenius-Stiftung, Fritz Thyssen Stiftung, Deutsche Herzstiftung, Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung., H2020 European Research Council
Awards: G1183566575, Mitochondrial Cristae Biogenesis, G1905259079, G2204319727, G2347632252, G2493537716, G2732538412, G2966517189, G2973303600, G3290298714, G3618156199, NAD Metabolismus in hereditären Kardiomyopathien, G434337789, G4355699489, G5890406466, Untersuchung von funktionellen und molekularen Mechanismen der Arrhythmieinduzierten Kardiomyopathie (AIC): Effekte von Vorhofflimmern auf den linken Ventrikel, Die Bedeutung der mitochondrialen CalciumHomöostase bei der Arrhythmogenese bei Patienten mit Vorhofflimmern., G6231867535, e:Bio - Modul II - Verbundprojekt: CaRNAtion: Therapeutische und diagnostische Verfahren basierend auf kardialer RNA Prozessierung, Teilvorhaben Göttingen, SFB 1525: Kardioimmune Schnittstellen, G7790951799, G8538526401, G973360009
OpenAlex ID: W7168178317
